TIRZEPATIDE (GIP/GLP-1)

Form: Lyophilized powder
Purity: >99%

TIRZEPATIDE (GIP/GLP-1) is a dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifying the effects of both incretin hormones.

This dual action enhances insulin secretion, reduces glucagon levels, and improves glucose regulation more effectively than single-pathway agonists. Additionally, GIP/GLP-1 can influence metabolic signaling pathways to support energy balance and lipid metabolism, contributing to improved nutrient processing and storage.

Comprised of 39 amino acids, GIP/GLP-1, a synthetic analog of the gastric inhibitory polypeptide (GIP), stands as a comparatively large peptide that appears to exert physiological potential through targeting and binding to GIP and GLP-1 (glucagon-like peptide-1) receptors.

Through this possible binding mechanism, TZ GIP/GLP-1 may stimulate insulin release from pancreatic cells, potentially enhancing glucose metabolism. Notably, the long-term presentation of TZ GIP/GLP-1 has been reported by researchers to elicit an apparent increase in adiponectin levels. Scientific investigations have indicated that TZ GIP/GLP-1 may exhibit an array of actions, including possible suppression of appetite, reduction of circulating insulin levels, and possible improvement of insulin sensitivity.